Pfizer announced on Thursday that it is making progress in the development of a once-daily weight loss pill, which the company believes could compete in the GLP-1 market. Meanwhile, the U.S. Food and Drug Administration (FDA) has not approved Novo Nordisk’s once-weekly insulin. Additionally, the U.S. Federal Trade Commission (FTC) released a report indicating that pharmacy benefit managers (PBMs) are increasing the prices of drugs.
Explore these stories and more pharmaceutical news highlights from this week.